Premature psychotherapy termination in an outpatient treatment program for personality disorders: a survival analysis.

OBJECTIVE: Psychological treatment for patients with personality disorders (PD) is plagued with a high proportion of early dropouts, and attempts to identify risk factors for attrition have generated very few conclusive results. The purpose of the present study is to identify significant predictors of early treatment termination in a long-term psychotherapy program for PD. METHODS: Data was retrospectively retrieved from 174 files of patients who began long-term psychotherapy in an outpatient treatment program in Quebec City, Canada. Socio-demographic, initial disturbance, and diagnostic variables were considered for prediction, along with a measure specifically designed to identify PD patients at risk of dropping out early from psychotherapy, the Treatment Attrition-Retention Scale for Personality Disorders (TARS-PD). Survival analysis using Cox proportional hazard regression was performed to identify significant predictors. RESULTS: Results using univariate Cox proportional hazards regressions revealed that unemployment, Global Assessment of Functioning scores, and recent hetero-aggressive behavior were significant predictors of early dropout in the first six months of therapy. Adjusting for these three confounders, four of the factor scores from the TARS-PD (Narcissism, Secondary gains, Low distress, and Cluster A features) were significantly associated with dropout in univariate Cox proportional hazards regressions. Secondary gains and Narcissism remained significant predictors after entering all five TARS-PD factors in a multivariate Cox proportional hazards regression adjusting for confounders. CONCLUSIONS: Taking into consideration specific treatment prognosis variables, such as those measured by the TARS-PD, might be more useful for dropout prediction in PD patients in comparison with more general demographic and diagnostic variables.

Premature Termination of Psychotherapy in Patients With Borderline Personality Disorder: A Cluster-Analytic Study.

The goal of the present study was to establish profiles of patients with borderline personality disorder (BPD) who dropped out early from an outpatient psychotherapy program. From a sample of 56 BPD patients who dropped out after the first of a three-year program, a TwoStep cluster analysis procedure was performed, using the five factors of the Treatment Attrition-Retention Scale for Personality Disorders (Gamache et al., J Pers Disord 1-21, 2017) and the Global Assessment of Functioning score (Spitzer et al., Global Assessment of Functioning [GAF] Scale. In Sederer LI, Dickey B [Eds], Outcomes assessment in clinical practice [pp 76-78]. Baltimore, MD: Walter and Williams) as clustering variables. Four clusters emerged: Higher-functioning, Narcissistic features/entitlement, Pseudo-normality, and Highly dysfunctional. Differences between the clusters were found on sex, occupational status, and presence of antisocial features. These findings could help both identify BPD patients at potential risk of dropping out of psychotherapy and adjust interventions accordingly to reduce premature termination.

Development and Validation of the Treatment Attrition-Retention Scale for Personality Disorders.

This study is an investigation of the psychometric properties of the Treatment Attrition-Retention Scale for Personality Disorders (TARS-PD), an instrument developed to identify patients with personality disorder (PD) at risk of early dropout from psychotherapy. In a first study, assessment files from 320 patients referred for PD evaluation at an outpatient clinic were examined to assess the instrument's inter-rater reliability, construct validity, and discriminant validity. Results showed that the global scale could be scored with excellent reliability. Exploratory factor analysis identified five factors: Narcissism, Psychopathy, Secondary gains, Low motivation, and Cluster A features. A second study focused on the scale's predictive validity. The TARS-PD showed high specificity (94%) in identifying dropouts, using a cut-off of ≥ 10. Both global and factor scores from the TARS-PD were significant predictors of treatment status (dropout vs. continuation) at 6 months. The scale should be considered promising for PD evaluation and treatment planning.

Feeling but not caring: empathic alteration in narcissistic men with high psychopathic traits.

Psychopathy is a personality disorder characterized by specific interpersonal-affective deficits and social deviance often marked by reduced empathy and decreased affective response to the suffering of others. However, recent findings in community samples suggest that the somatosensory resonance to other's pain measured with electroencephalography (EEG) is increased by psychopathic traits. This study aimed at comparing both the response to physical pain and the observation of pain being inflicted to another person in individuals with clinically significant psychopathic traits, namely patients with severe narcissistic personality disorder (NPD, n=11), and community controls (CC, n=13). The gating of somatosensory responses to a tactile steady-state stimulation (25 Hz) during the observation of pain-evoking and non-painful visual stimuli of hands was measured using EEG. Pain thresholds were assessed with a quantitative sensory testing (QST) battery. NPD compared with CC subjects showed similar thermal pain thresholds, but significantly higher pain pressure thresholds (PPT). Significantly greater somatosensory gating (SG) during the anticipation and the observation of pain in others was observed in NPD compared with CC subjects, but this difference was not associated with differences in self-pain perception. SG to pain observation was positively correlated with the Impulsivity-Egocentricity (IE) dimension of psychopathy. These findings demonstrated a stronger somatosensory resonance in the high psychopathic trait NPD group that suggests an increased somatic representation of observed pain despite lower dispositional empathy.

The modulation of somatosensory resonance by psychopathic traits and empathy.

A large number of neuroimaging studies have shown neural overlaps between first-hand experiences of pain and the perception of pain in others. This shared neural representation of vicarious pain is thought to involve both affective and sensorimotor systems. A number of individual factors are thought to modulate the cerebral response to other's pain. The goal of this study was to investigate the impact of psychopathic traits on the relation between sensorimotor resonance to other's pain and self-reported empathy. Our group has previously shown that a steady-state response to non-painful stimulation is modulated by the observation of other people's bodily pain. This change in somatosensory response was interpreted as a form of somatosensory gating (SG). Here, using the same technique, SG was compared between two groups of 15 young adult males: one scoring very high on a self-reported measure of psychopathic traits [60.8 ± 4.98; Levenson's Self-Report Psychopathy Scale (LSRP)] and one scoring very low (42.7 ± 2.94). The results showed a significantly greater reduction of SG to pain observation for the high psychopathic traits group compared to the low psychopathic traits group. SG to pain observation was positively correlated with affective and interpersonal facet of psychopathy in the whole sample. The high psychopathic traits group also reported lower empathic concern (EC) scores than the low psychopathic traits group. Importantly, primary psychopathy, as assessed by the LSRP, mediated the relation between EC and SG to pain observation. Together, these results suggest that increase somatosensory resonance to other's pain is not exclusively explained by trait empathy and may be linked to other personality dimensions, such as psychopathic traits.

[Dysregulation of the executive system and theory of mind: clinical interest of a neuroscientific conception of BPD]. / Intérêt clinique d'une conception neuroscientifique du trouble de personnalité limite : dysfonctionnements du système exécutif et de la théorie de l'esprit.

Borderline personality disorder (BPD) is a complex psychopathology. Through recent developments, neuroscience is able to contribute to better understanding the neurobiological underpinnings of BPD manifestations. This article aims to demonstrate that BPD is in part due to executive and frontal dysregulation of the mechanisms responsible for the optimal functioning of inferences specific to theory of mind. To do so, four types of observations will be examined: parallels between frontal personality and BPD, the presence of frontal cognitive deficits in BPD, the consequences of childhood abuse and neglect on brain development and finally, the results of brain imagery in BPD. This article follows in the path of a growing interest in the integration of the neuroscientific perspective of BPD to current conceptualisations in psychopathology. The final aim is to try to offer an understanding of BPD manifestations that avoids the traditional splitting between mind and brain-psychology and biology-and to show the numerous associations between clinical psychology and neurobiology.

Signs of insomnia in borderline personality disorder individuals.

STUDY OBJECTIVES: Recent findings suggest few differences in sleep continuity and quality between borderline personality disorder individuals (BPD-I) and good sleepers (GS). Nonetheless, BPD-I show marked discrepancies between subjective and objective sleep measures. The objective of this study was to document sleep in BPD-I, GS, and insomnia sufferers (paradoxical, Para-I; psychophysiological, Psy-I). PARTICIPANTS: Twelve BPD-I (mean age 33.3 years), 15 GS (mean age 34.1 years), 15 Para-I (mean age 41.1 years), and 15 Psy-I (mean age 36.6 years). METHODS: Participants underwent 3 consecutive nights of polysomnography recordings. All participants completed a clinical interview and 2 weeks of sleep diaries. BPD-I received DIB-R assessment. Participants were not suffering from any other psychopathology and were drug free. RESULTS: Subjectively, BPD-I and GS laboratory sleep reports were similar. However, Psy-I and Para-I took longer to fall asleep, were awake longer after sleep onset and during the night, slept less, and had lower sleep efficiency than both GS and BPD-I (p < 0.05). Objectively, BPD-I, Psy-I, and Para-I had longer sleep onset, shorter sleep time, and lower sleep efficiency on all 3 nights than GS (p < 0.05). Furthermore, BPD-I had more stage 4 (both in proportion and time) than Para-I on all 3 nights (p < 0.05). CONCLUSION: Results suggest that BPD-I suffer from insomnia. While BDI-I reported feeling less refreshed upon awakening, they spent more time in stage 4 than other individuals. As BPD-I are very sensitive to loneliness and interpersonal stressors, laboratory settings might provide a secure context facilitating sleep.

Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.

BACKGROUND: Recent studies indicate that atypical neuroleptics may be safe and useful in treating many symptoms of borderline personality disorder (BPD), including impulsivity, which can constitute the core dimension of this pathology. This study aimed to evaluate the efficacy and safety of quetiapine in patients with well-defined BPD. It was hypothesized that quetiapine would reduce impulsivity (primary hypothesis) and also affective and micropsychotic symptoms, resulting in improved social and global functioning (secondary hypothesis). METHOD: Twenty-three outpatients with BPD according to DSM-IV criteria and the revised Diagnostic Interview for Borderlines completed a 12-week open-label study with quetiapine. The study was conducted from May 2001 to May 2003. The clinical efficacy was assessed using the following: Hamilton Rating Scales for Depression and Anxiety, Hopelessness Scale, Brief Psychiatric Rating Scale, Barratt Impulsivity Scale, Buss-Durkee Hostility Inventory, Temperament and Character Inventory, Social Adjustment Scale, and Global Assessment of Functioning. RESULTS: The mean daily dose of quetiapine (251 +/- 50 mg; range, 175-400 mg) was well tolerated. Impulsivity was significantly improved by quetiapine (p = .0015), as were most of our outcome measures: hostility, depression, anxiety, character dimensions, and social and global functioning (p < .05). In the small subgroup of patients with psychotic symptoms at baseline, there was a significant reduction in these symptoms (N = 8, p = .018). CONCLUSION: In a sample of patients with severe BPD without or with only few psychotic symptoms, a low dose of quetiapine was associated with a strong positive clinical impact, including improvement of impulsivity.